Skip to Content
Print Share

Generic Adderall Availability

See also: Generic Adderall XR

Adderall is a brand name of amphetamine/dextroamphetamine, approved by the FDA in the following formulation(s):

ADDERALL 10 (amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate - tablet;oral)

  • Manufacturer: TEVA WOMENS
    Approval date: February 13, 1996
    Strength(s): 2.5MG;2.5MG;2.5MG;2.5MG [RLD] [AB]
  • Manufacturer: TEVA WOMENS
    Approval date: August 31, 2000
    Strength(s): 3.125MG;3.125MG;3.125MG;3.125MG [RLD] [AB]
  • Manufacturer: TEVA WOMENS
    Approval date: August 31, 2000
    Strength(s): 3.75MG;3.75MG;3.75MG;3.75MG [RLD] [AB]
  • Manufacturer: TEVA WOMENS
    Approval date: February 13, 1996
    Strength(s): 5MG;5MG;5MG;5MG [RLD] [AB]
  • Manufacturer: TEVA WOMENS
    Approval date: May 12, 1997
    Strength(s): 7.5MG;7.5MG;7.5MG;7.5MG [RLD] [AB]
  • Manufacturer: TEVA WOMENS
    Approval date: May 12, 1997
    Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [RLD] [AB]
  • Manufacturer: TEVA WOMENS
    Approval date: August 31, 2000
    Strength(s): 1.875MG;1.875MG;1.875MG;1.875MG [RLD] [AB]

All of the above formulations have been discontinued.

Has a generic version of Adderall been approved?

A generic version of Adderall has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Adderall and have been approved by the FDA:

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate tablet;oral)

  • Manufacturer: ACTAVIS ELIZABETH
    Approval date: February 5, 2016
    Strength(s): 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB], 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB]
  • Manufacturer: ALVOGEN MALTA
    Approval date: July 28, 2017
    Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB]
  • Manufacturer: AUROLIFE PHARMA LLC
    Approval date: November 27, 2013
    Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB]
  • Manufacturer: BARR
    Approval date: February 11, 2002
    Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB]
  • Manufacturer: BARR
    Approval date: March 19, 2003
    Strength(s): 1.875MG;1.875MG;1.875MG;1.875MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB]
  • Manufacturer: EPIC PHARMA LLC
    Approval date: June 19, 2002
    Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB]
  • Manufacturer: EPIC PHARMA LLC
    Approval date: November 3, 2014
    Strength(s): 1.875MG;1.875MG;1.875MG;1.875MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB]
  • Manufacturer: MYLAN PHARMS INC
    Approval date: November 10, 2015
    Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB]
  • Manufacturer: NESHER PHARMS
    Approval date: October 31, 2017
    Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB]
  • Manufacturer: NUVO PHARM
    Approval date: December 28, 2017
    Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB]
  • Manufacturer: SANDOZ
    Approval date: June 14, 2002
    Strength(s): 2.5MG;2.5MG;2.5MG;2.5MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB]
  • Manufacturer: SANDOZ
    Approval date: September 27, 2002
    Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB]
  • Manufacturer: SPECGX LLC
    Approval date: October 7, 2003
    Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB]
  • Manufacturer: SUN PHARM INDUSTRIES
    Approval date: September 9, 2003
    Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB]
  • Manufacturer: SUNGEN PHARMA
    Approval date: December 7, 2018
    Strength(s): 1.25MG;1.25MG;1.25MG;1.25MG [AB], 1.875MG;1.875MG;1.875MG;1.875MG [AB], 2.5MG;2.5MG;2.5MG;2.5MG [AB], 3.125MG;3.125MG;3.125MG;3.125MG [AB], 3.75MG;3.75MG;3.75MG;3.75MG [AB], 5MG;5MG;5MG;5MG [AB], 7.5MG;7.5MG;7.5MG;7.5MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Adderall. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Rapid immediate release oral dosage form
    Patent 6,384,020
    Issued: May 7, 2002
    Inventor(s): Henry H.; Flanner & Rong-Kun; Chang & Jill E.; Pinkett & Sandra E.; Wassink & Lisa R.; White
    Assignee(s): Shire Laboratories, Inc.

    A pharmaceutical composition comprising lactitol and one or more amphetamine salts in a rapid release formulation.

    Patent expiration dates:

    • July 6, 2020
    • January 6, 2021
      ✓ 
      Pediatric exclusivity

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps
Hide